Long-term data show benefit of DETROL LA as first-line therapy for overactive bladder

isodes associated with overactive bladder.

Since its introduction in January 2001, DETROL LA has become the number one prescribed treatment for overactive bladder in the United States and has been prescribed for more than seven million patients worldwide.

DETROL LA is indicated for the treatment of overactive bladder with symptoms of urge incontinence, urgency and frequency.

DETROL LA is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma and in patients who have demonstrated hypersensitivity to the drug or its ingredients.

Patients with the following conditions should be treated with caution: renal impairment, bladder outflow obstruction, gastrointestinal obstructive disorders, controlled narrow-angle glaucoma, and significantly reduced hepatic function. Dry mouth was the most frequently reported adverse event (DETROL LA 23 percent vs. placebo 8 percent); others (> 4 percent) included headache (DETROL LA 6 percent vs. placebo 4 percent), constipation (DETROL LA 6 percent vs. placebo 4 percent), and abdominal pain (DETROL LA 4 percent vs. placebo 2 percent).



Page: 1 2 3

Related medicine news :

1. Long-term high consumption of red and processed meat linked with increased risk for colon cancer
2. Long-term benefits for newly diagnosed patients with CML receiving first-line therapy with imatinib
3. Long-term obesity linked to loss of brain tissue in women
4. Long-term study demonstrated ADDERALL XR is an effective option to treat adolescents with ADHA
5. Long-term study proves ADDERALL XR is a safe and effective option to treat adults with ADHD
6. Long-term use of antibiotics possibly linked with increased risk of breast cancer
7. Long-term follow-up of mortality in patients with community-acquired pneumonia
8. Long-term outcome of epilepsy surgery is favorable for many
9. Long-term ERT in postmenopausal women with Alzheimers may worsen memory
10. Long-term avoidance of milk in children results in poor bone health
11. Long-term effects of tirofiban similar to abciximab in patients having coronary-artery angioplasty

Post Your Comments:
(Date:10/9/2015)... ... 2015 , ... Amada Senior Care, premier provider of non-medical ... Maryland – its Bethesda location. Amada franchise partner Steve Schultz came ... consultant to many of the largest construction firms in the Mid-Atlantic region. He ...
(Date:10/9/2015)... ... ... Smanos was featured on NewsWatch as part of its monthly Tech Report, which ... expert and special reporter for NewsWatch, conducted the review and shared with viewers how ... and age it’s more important than ever to keep homes and dorms safe and ...
(Date:10/9/2015)... ... , ... A variety of race options will be available for the Run 4 Recovery sponsored ... at Al Lopez Park, 4810 North Himes Avenue, in Tampa. The family friendly event will ... run or walk and a one-mile walk, followed by an award ceremony at 10 a.m. ...
(Date:10/9/2015)... , ... October 09, 2015 , ... Dignity Health named ... General Hospital Emergency Room – Chandler–McQueen opening later this month. The new ... this year in the West Valley. , “Dr. Morro is an excellent leader ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... County, North Carolina and nearby communities, launched a new website to mark Domestic ... of domestic violence to find help immediately, whether through an emergency hotline, support ...
Breaking Medicine News(10 mins):
(Date:10/9/2015)... , Oct. 9, 2015 Ansun BioPharma ... Disease Society of America ) regarding the compassionate use ... patient on a respirator who was co-infected with influenza ... five-day course of therapy, O 2 requirement was ... patient was able to go off the respirator on ...
(Date:10/9/2015)... El ,JCA-Mauvernay Award 2015, se ha otorgado ... Junko Takita    --> El ,JCA-Mauvernay ... Yutaka Kondo y Junko Takita    ... ha otorgado a los doctores Yutaka Kondo ... compañía biofarmacéutica global con sede enSuiza, presentará el ,JCA-Mauvernay Award, el 10 de ...
(Date:10/8/2015)... ® ) in adult ... NOCT study also assessed the compliance, safety, patient ... ® ) in adult patients undergoing screening, surveillance ... the compliance, safety, patient acceptability and tolerability of ... top line results for its phase III study, ...
Breaking Medicine Technology:
Cached News: